Professor of Medicine (Cardiology)
Georgetown University Medical Center
Associate Director, Division of Cardiology
MedStar Washington Hospital Center
Washington, District of Columbia
Session Moderator
SESSION 31: ADVANCES IN MEDICAL DIAGNOSIS AND TREATMENTS IN VASCULAR PATIENTS; NEW ANTI-ATHEROGENIC DRUGS AND LIPID MANAGEMENT
Session Moderator
SESSION 32: CATHETER-BASED TREATMENTS FOR RESISTANT HYPERTENSION; MANAGEMENT OF CARDIAC PROBLEMS, CORONARY DESS, SMOKING AND TRANSFUSION IN VASCULAR SURGERY PATIENTS; PREVENTING VASCULAR AND CARDIAC COMPLICATIONS
Presenter
SESSION 25: LOWER EXTREMITY TOPICS RELATED TO BTK LESION DCBS AND STENTING – STANDARD AND NEW BIORESORBABLE
Presenter
SESSION 31: ADVANCES IN MEDICAL DIAGNOSIS AND TREATMENTS IN VASCULAR PATIENTS; NEW ANTI-ATHEROGENIC DRUGS AND LIPID MANAGEMENT
Presenter
SESSION 31: ADVANCES IN MEDICAL DIAGNOSIS AND TREATMENTS IN VASCULAR PATIENTS; NEW ANTI-ATHEROGENIC DRUGS AND LIPID MANAGEMENT
SESSION 31: ADVANCES IN MEDICAL DIAGNOSIS AND TREATMENTS IN VASCULAR PATIENTS; NEW ANTI-ATHEROGENIC DRUGS AND LIPID MANAGEMENT
Session Moderator
SESSION 32: CATHETER-BASED TREATMENTS FOR RESISTANT HYPERTENSION; MANAGEMENT OF CARDIAC PROBLEMS, CORONARY DESS, SMOKING AND TRANSFUSION IN VASCULAR SURGERY PATIENTS; PREVENTING VASCULAR AND CARDIAC COMPLICATIONS
Presenter
SESSION 25: LOWER EXTREMITY TOPICS RELATED TO BTK LESION DCBS AND STENTING – STANDARD AND NEW BIORESORBABLE
Bioresorbable Magnesium Scaffold (Stent — BIOTRONIK) Has Been Improved For Lower Extremity And Coronary Lesions: Current Status, Advantages And Limitations
9:11 AM - 9:16 AM
Presenter
SESSION 31: ADVANCES IN MEDICAL DIAGNOSIS AND TREATMENTS IN VASCULAR PATIENTS; NEW ANTI-ATHEROGENIC DRUGS AND LIPID MANAGEMENT
The Importance Of Decreasing Inflammation (As Reflected By C-Reactive Protein Levels) With Old And New Drugs; New Information On The Effect Of Elevated Lp(a) And Elevated Triglycerides: What Drugs Can Lower Them (Mulvalapin And Zerlasiran; Vascepa)
7:16 AM - 7:21 AM
Presenter
SESSION 31: ADVANCES IN MEDICAL DIAGNOSIS AND TREATMENTS IN VASCULAR PATIENTS; NEW ANTI-ATHEROGENIC DRUGS AND LIPID MANAGEMENT
Update On The New Anti-Atherosclerosis Vaccine (AtheroVax): A Drug To Produce Lifelong LDL-C Lowering With A Single Gene Modifying Treatment: The Heart-1 Gene-Editing Trial: How Does AtheroVax Work And Results To Date
7:28 AM - 7:33 AM